The Competition Commission (Commission) today published a revised Leniency Policy for Undertakings Engaged in Cartel Conduct and a new Leniency Policy for Individuals Involved in Cartel Conduct to enhance the effectiveness and transparency of its leniency programme for cartel conduct, which will strengthen cartel detection, enforcement, and victim recovery.
Leniency is proven to be an effective investigative tool used by competition authorities around the world to combat cartels, including bid rigging, price fixing, market sharing and output restriction, which are serious anti-competitive conduct under the Competition Ordinance (Cap. 619) (Ordinance). Investigations resulting from leniency have also significantly facilitated private damages actions brought by victims of cartels around the world.
Based on its experience accumulated since the Ordinance came into full effect, the Commission has reviewed and revised its leniency framework with a view to strengthening its efficacy and comprehensiveness, providing stronger and clearer incentives for a cartel member to stop the cartel conduct and report it to the Commission, thereby strengthening enforcement and furthering victim recovery.
Full Content: Competition Commission
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan